Say hello to MassDevice +3, a bite-sized view of the top three medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 3 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
Boston Scientific said it’s building value-based offerings into its cardiovascular business to help its hospital customers optimize their operations, enlisting MedAxiom and TogetherMD to help build its Advantics service.
Advantics offers a variety of solutions for healthcare providers, including performance optimization, capital financing, care pathway transformation and patient management programs, Boston Scientific said. Advantics “emphasizes collaboration to meet unique customer needs,” the company said. Read more
Smith & Nephew CEO Olivier Bohuon said today that the British healthcare giant is “still working hard” at finding acquisitions, seeking emerging market opportunities, bolt-ons and early-stage opportunities.
“[W]e are looking forward to acquire distributors in the emerging market. That is our strategy to become closer to the customers and avoid the distributor in the countries,” Bohuon said during a conference call discussing Smith & Nephew’s 1st-quarter results. Read more
Medtronic said it’s launching a study of a new, combination treatment for atrial fibrillation using renal denervation and cardiac ablation.
The Fridley, Minn.-based medical device giant said the 245-patient Symplicity AF trial is a prospective, randomized, multi-center feasibility study. It’s designed to compare RDN and pulmonary vein isolation using a cardiac ablation catheter with PVI alone, Medtronic said. Read more